vs
Foghorn Therapeutics Inc.（FHTX）与Maase Inc.（MAAS）财务数据对比。点击上方公司名可切换其他公司
Maase Inc.的季度营收约是Foghorn Therapeutics Inc.的1.1倍（$9.9M vs $9.2M）
Foghorn Therapeutics是一家临床阶段生物技术企业，专注于开发靶向染色质调控系统的创新疗法，用于治疗多种癌症及其他严重疾病，目前推进多款靶向候选药物管线，通过自主研发与战略合作服务全球患者群体。
FHTX vs MAAS — 直观对比
营收规模更大
MAAS
是对方的1.1倍
$9.2M
损益表 — Q4 FY2025 vs Q2 FY2023
| 指标 | | |
|---|---|---|
| 营收 | $9.2M | $9.9M |
| 净利润 | $-21.7M | — |
| 毛利率 | — | 78.7% |
| 营业利润率 | -258.2% | -55.9% |
| 净利率 | -234.3% | — |
| 营收同比 | 223.8% | — |
| 净利润同比 | -11.1% | — |
| 每股收益（稀释后） | $-0.35 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FHTXMAAS
| Q4 25 | $9.2M | — | ||
| Q3 25 | $8.2M | — | ||
| Q2 25 | $7.6M | — | ||
| Q1 25 | $6.0M | — | ||
| Q4 24 | $2.9M | — | ||
| Q3 24 | $7.8M | — | ||
| Q2 24 | $6.9M | — | ||
| Q1 24 | $5.0M | — |
净利润FHTXMAAS
| Q4 25 | $-21.7M | — | ||
| Q3 25 | $-15.8M | — | ||
| Q2 25 | $-17.9M | — | ||
| Q1 25 | $-18.8M | — | ||
| Q4 24 | $-19.5M | — | ||
| Q3 24 | $-19.1M | — | ||
| Q2 24 | $-23.0M | — | ||
| Q1 24 | $-25.0M | — |
营业利润率FHTXMAAS
| Q4 25 | -258.2% | — | ||
| Q3 25 | -226.9% | — | ||
| Q2 25 | -279.2% | — | ||
| Q1 25 | -385.0% | — | ||
| Q4 24 | -840.5% | — | ||
| Q3 24 | -305.5% | — | ||
| Q2 24 | -386.6% | — | ||
| Q1 24 | -558.3% | — |
净利率FHTXMAAS
| Q4 25 | -234.3% | — | ||
| Q3 25 | -194.4% | — | ||
| Q2 25 | -237.3% | — | ||
| Q1 25 | -316.4% | — | ||
| Q4 24 | -682.9% | — | ||
| Q3 24 | -244.9% | — | ||
| Q2 24 | -333.6% | — | ||
| Q1 24 | -495.4% | — |
每股收益（稀释后）FHTXMAAS
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $-0.25 | — | ||
| Q2 25 | $-0.28 | — | ||
| Q1 25 | $-0.30 | — | ||
| Q4 24 | $-0.23 | — | ||
| Q3 24 | $-0.31 | — | ||
| Q2 24 | $-0.45 | — | ||
| Q1 24 | $-0.59 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.9M | $10.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-108.5M | $31.6M |
| 总资产 | $198.1M | $47.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FHTXMAAS
| Q4 25 | $80.9M | — | ||
| Q3 25 | $89.3M | — | ||
| Q2 25 | $72.6M | — | ||
| Q1 25 | $61.0M | — | ||
| Q4 24 | $55.5M | — | ||
| Q3 24 | $57.7M | — | ||
| Q2 24 | $138.9M | — | ||
| Q1 24 | $79.3M | — |
股东权益FHTXMAAS
| Q4 25 | $-108.5M | — | ||
| Q3 25 | $-89.7M | — | ||
| Q2 25 | $-76.7M | — | ||
| Q1 25 | $-61.7M | — | ||
| Q4 24 | $-45.5M | — | ||
| Q3 24 | $-28.3M | — | ||
| Q2 24 | $-14.3M | — | ||
| Q1 24 | $-97.5M | — |
总资产FHTXMAAS
| Q4 25 | $198.1M | — | ||
| Q3 25 | $205.0M | — | ||
| Q2 25 | $226.2M | — | ||
| Q1 25 | $258.7M | — | ||
| Q4 24 | $284.0M | — | ||
| Q3 24 | $308.4M | — | ||
| Q2 24 | $328.6M | — | ||
| Q1 24 | $255.0M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.3M | $-18.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-18.3M |
| 自由现金流率自由现金流/营收 | — | -184.4% |
| 资本支出强度资本支出/营收 | 0.0% | 1.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FHTXMAAS
| Q4 25 | $-22.3M | — | ||
| Q3 25 | $-18.9M | — | ||
| Q2 25 | $-21.0M | — | ||
| Q1 25 | $-24.0M | — | ||
| Q4 24 | $-24.5M | — | ||
| Q3 24 | $-21.0M | — | ||
| Q2 24 | $-25.5M | — | ||
| Q1 24 | $-29.3M | — |
自由现金流FHTXMAAS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-21.0M | — | ||
| Q1 25 | $-24.0M | — | ||
| Q4 24 | $-25.0M | — | ||
| Q3 24 | $-21.3M | — | ||
| Q2 24 | $-25.6M | — | ||
| Q1 24 | $-29.4M | — |
自由现金流率FHTXMAAS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -278.2% | — | ||
| Q1 25 | -403.2% | — | ||
| Q4 24 | -875.3% | — | ||
| Q3 24 | -273.0% | — | ||
| Q2 24 | -371.0% | — | ||
| Q1 24 | -583.1% | — |
资本支出强度FHTXMAAS
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 16.8% | — | ||
| Q3 24 | 4.0% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 2.0% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FHTX
暂无分部数据
MAAS
| Wealth management | $7.8M | 78% |
| Insurance consulting | $1.0M | 10% |
| Other | $975.0K | 10% |
| Asset management | $168.0K | 2% |
